Dynavax Technologies (DVAX) Scheduled to Post Quarterly Earnings on Thursday

Dynavax Technologies (NASDAQ:DVAX) is set to announce its earnings results after the market closes on Thursday, November 7th. Analysts expect the company to announce earnings of $0.10 per share for the quarter. Investors that are interested in registering for the company’s conference call can do so using this link.

Dynavax Technologies (NASDAQ:DVAX) last announced its quarterly earnings results on Tuesday, August 6th. The biopharmaceutical company reported $0.08 EPS for the quarter, topping the consensus estimate of $0.06 by $0.02. The company had revenue of $73.80 million during the quarter, compared to analyst estimates of $76.92 million. Dynavax Technologies had a return on equity of 2.76% and a net margin of 6.88%. During the same period in the prior year, the firm posted $0.03 earnings per share. On average, analysts expect Dynavax Technologies to post $0 EPS for the current fiscal year and $0 EPS for the next fiscal year.

Dynavax Technologies Stock Performance

Shares of NASDAQ:DVAX opened at $12.01 on Wednesday. The firm has a market capitalization of $1.57 billion, a PE ratio of 109.19 and a beta of 1.34. The company has a debt-to-equity ratio of 0.35, a current ratio of 14.18 and a quick ratio of 13.18. The business has a 50-day moving average of $11.09 and a two-hundred day moving average of $11.22. Dynavax Technologies has a 12 month low of $9.74 and a 12 month high of $15.01.

Analyst Upgrades and Downgrades

Several equities research analysts have commented on DVAX shares. HC Wainwright restated a “buy” rating and set a $29.00 price target on shares of Dynavax Technologies in a research note on Tuesday, October 15th. The Goldman Sachs Group lowered their target price on Dynavax Technologies from $20.00 to $15.00 and set a “neutral” rating for the company in a research note on Thursday, August 8th.

About Dynavax Technologies

Dynavax Technologies Corporation, a commercial stage biopharmaceutical company, focuses on developing and commercializing vaccines in the United States. It markets HEPLISAV-B, a hepatitis B vaccine for prevention of infection caused by all known subtypes of hepatitis B virus in age 18 years and older in the United States and Europe.